Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers

Next Previous
Trial Profile

A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexiganan (Primary) ; Antibacterials
  • Indications Bacterial infections; Diabetic foot ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms OneStep-2
  • Sponsors Dipexium Pharmaceuticals

Most Recent Events

  • 25 Oct 2016 Primary endpoint has not been met. (Clinical Response), as reported by a Dipexium media release.
  • 25 Oct 2016 Results published in the Dipexium media release.
  • 20 Oct 2016 According to a Dipexium media release, data tables and listings from this and another phase III trial are currently being produced and evaluated by the Company's scientific advisors according to the pre-specified data review procedure.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top